Unquestionably, for the multinational drug companies, much of this does come down to the quality of science, where Canada punches well above its weight. Canada truly outstrips others, despite our size, when it comes to both leadership in and conducting of clinical trials. Where we unfortunately haven't seen that conversion is into the manufacturing of products and services, and those who are much more expert than I am in the econometrics of drug companies and what makes pharma choose a nation to be in. It usually comes down to labour costs, taxation and the attractiveness that jurisdictions can offer.
We know that in the United States, for example, state governments make it very, very attractive in certain parts of the country to come and locate, particularly for early start-ups, and often this is the case with those reagents and actions that are found that we wish to have taken to phase-one clinical trials.
It's often a group of remarkable investigators who discover something. They are then wooed by jurisdictions where perhaps more ambitiously there is the waiving of, for example, municipal, provincial and federal levels of taxation for a period of time. In terms of labour supports, they have made it very economically attractive. If we think backwards, many years ago the Province of Quebec made a concerted effort around—